As most kinase inhibitors show off-target effects, we pretreated purified CLL cells (n = 2) with an AXL inhibitor21, a BCR-ABL inhibitor asciminib or a JAK2 inhibitor fedratinib for 2 h prior exposing to H2O2. The gene discussed is AXL; the disease is B-cell chronic lymphocytic leukemia.